Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TNXP

Tonix Pharmaceuticals Holding Corp

Nov 28 • 02:12PM ET

0.5265

Dollar change +0.0375
Percentage change 7.67	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-11.23	Insider Own	0.07%	Shs Outstand	23.85M	Perf Week	9.46%
Market Cap	12.56M	Forward P/E	-	EPS next Y	-3.98	Insider Trans	0.00%	Shs Float	23.83M	Perf Month	-3.99%
Income	-123.42M	PEG	-	EPS next Q	-1.33	Inst Own	15.58%	Short Float / Ratio	0.42% / 0.33	Perf Quarter	-44.29%
Sales	3.99M	P/S	3.15	EPS this Y	61.77%	Inst Trans	101.93%	Short Interest	0.10M	Perf Half Y	-67.70%
Book/sh	6.80	P/B	0.08	EPS next Y	49.06%	ROA	-63.37%	Target Price	8.67	Perf Year	-78.70%
Cash/sh	0.29	P/C	1.82	EPS next 5Y	-	ROE	-69.20%	52W Range	0.43 - 9.81	Perf YTD	-78.39%
Dividend	-	P/FCF	-	EPS past 5Y	79.97%	ROI	-101.54%	52W High	-94.63%	Beta	2.35
Dividend %	-	Quick Ratio	1.02	Sales past 5Y	0.00%	Gross Margin	-49.94%	52W Low	22.44%	ATR	0.04
Employees	117	Current Ratio	1.77	Sales Q/Q	-	Oper. Margin	-3103.01%	RSI (14)	52.25	Volatility	5.48% 6.26%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	57.74%	Profit Margin	-3094.01%	Rel Volume	2.17	Prev Close	0.49
Shortable	Yes	LT Debt/Eq	0.01	Earnings	Nov 09 AMC	Payout	-	Avg Volume	300.24K	Price	0.53
Recom	1.00	SMA20	6.91%	SMA50	-8.68%	SMA200	-73.37%	Volume	480,368	Change	7.67%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy	$4
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy	$6
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform	$18 → $10
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform	$18
Feb-17-15	Reiterated	ROTH Capital	Buy	$10 → $12
Sep-29-14	Reiterated	ROTH Capital	Buy	$17 → $10

Today 07:00AM	Tonix Pharmaceuticals to Present at Two Upcoming Investor Conferences in December (GlobeNewswire) +7.67%
Nov-20-23 01:57PM	Tonix Pharmaceuticals' CEO reveals next-generation COVID vaccine technology chosen for key program (News Direct)
01:53PM	Tonix Pharmaceuticals finish Phase 3 trial of TNX-102 SL for management of Fibromyalgia (News Direct)
Nov-15-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Stage of Phase 3 RESILIENT Study of TNX-102 SL for the Management of Fibromyalgia (GlobeNewswire)
Nov-13-23 07:00AM	Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder (GlobeNewswire)
04:15PM	Loading…
Nov-09-23 04:15PM	Tonix Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Nov-02-23 08:00AM	Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials (GlobeNewswire)
Oct-31-23 05:00PM	Tonix Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder (GlobeNewswire)
Oct-30-23 07:00AM	Tonix Pharmaceuticals Announces New Data Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) in Heart Xenotransplantation in Animal Models at the ACS Clinical Congress and IPITA-IXA-CTRMS Joint Congress (GlobeNewswire)
Oct-26-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs (GlobeNewswire)
Oct-25-23 08:45AM	New Hope for Long COVID Sufferers (ACCESSWIRE)
Oct-19-23 07:00AM	Tonix Pharmaceuticals Presents Data from its Horsepox-Based Vaccine Development Platform at the World Vaccine Congress Europe (GlobeNewswire)
Oct-18-23 07:00AM	Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving TNX-1500 (Fc-modified dimeric anti-CD40L mAb) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models (GlobeNewswire)
Oct-16-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder (GlobeNewswire)
Oct-12-23 07:00AM	Tonix Pharmaceuticals to Present at the 2023 ThinkEquity Conference (GlobeNewswire)
07:00AM	Loading…
Oct-11-23 07:00AM	Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe (GlobeNewswire)
Oct-09-23 07:00AM	Tonix Pharmaceuticals Provides Overview of TNX-2900 Program for the Treatment of Prader-Willi Syndrome at the Foundation for Prader-Willi Research Family Conference (GlobeNewswire)
Oct-04-23 07:00AM	Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain (GlobeNewswire) +6.72%
Sep-28-23 09:00PM	Tonix Pharmaceuticals Announces Pricing of $4.5 Million Public Offering (GlobeNewswire) -5.26%
04:01PM	Tonix Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Sep-27-23 08:30AM	Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder (GlobeNewswire) -6.67%
Sep-26-23 10:18AM	TNXP: Encouraging Topline Results for Long COVID Trial (Zacks)
Sep-21-23 07:00AM	Tonix Pharmaceuticals Presents New Preclinical Data at Seventh International Cancer Immunotherapy Conference 2023 (GlobeNewswire) -7.21%
Sep-19-23 01:54PM	Tonix Pharmaceuticals releases positive results from Proof-Of-Concept Study on TNX-102 SL (News Direct)
Sep-18-23 07:00AM	Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress (GlobeNewswire) -6.50%
Sep-15-23 09:30AM	New to The Street Announces Episodes 510 and 511 Six Corporate Interviews, airings on Newsmax and FOX Business Network, Broadcastings Begin Saturday, September 16, 2023, at 3:30 PM ET (GlobeNewswire)
Sep-14-23 07:00AM	Tonix Pharmaceuticals Announces Poster Presentation Involving TNX-1700 in Preclinical Colorectal Cancer Models at the Seventh International Cancer Immunotherapy Conference 2023 (GlobeNewswire)
Sep-06-23 07:00AM	Tonix Pharmaceuticals Announces Commitment to Supply Tosymra® (sumatriptan Nasal Spray) 10 mg for Treatment of Acute Migraine to Meet Potential Increased Demand Following GSKs Planned Discontinuation of Imitrex® (sumatriptan) Nasal Spray After January 2024 (GlobeNewswire)
Sep-05-23 07:32AM	UPDATE 1-Tonix's long COVID drug fails to meet mid-stage trial goal (Reuters) -8.50%
07:05AM	Tonix's long COVID drug fails to meet mid-stage trial goal (Reuters)
07:00AM	Loading…
07:00AM	Tonix Pharmaceuticals Announces Topline Results from Phase 2 PREVAIL Proof-of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID (GlobeNewswire)
Aug-28-23 01:13PM	Tonix Pharmaceuticals begins Phase 1 trial of TNX-1500 in healthy participants (News Direct)
Aug-21-23 01:18PM	Tonix Pharmaceuticals begins Phase 1 trial of TNX-1500 in healthy participants (News Direct)
07:00AM	Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-801 as a Potential Vaccine to Prevent Mpox and Smallpox (GlobeNewswire)
Aug-17-23 07:00AM	Tonix Pharmaceuticals to Present at the August Virtual Investor Summit (GlobeNewswire)
Aug-16-23 07:00AM	Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers (GlobeNewswire)
Aug-10-23 04:30PM	Tonix Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
Aug-07-23 07:00AM	Tonix Pharmaceuticals Completes Clinical Phase of PREVAIL Proof-of-Concept Study of TNX-102 SL for the Treatment of Fibromyalgia-Type Long COVID (GlobeNewswire)
Aug-01-23 04:01PM	Tonix Pharmaceuticals Announces Closing of $7 Million Public Offering (GlobeNewswire)
07:00AM	Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia (GlobeNewswire)
Jul-31-23 07:00AM	Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 STROBE Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder (GlobeNewswire)
Jul-27-23 09:31PM	Tonix Pharmaceuticals Announces Pricing of $7 Million Public Offering (GlobeNewswire)
04:01PM	Tonix Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Jul-26-23 04:05PM	Tonix Pharmaceuticals Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023 (GlobeNewswire)
Jul-24-23 07:00AM	Tonix Pharmaceuticals Announces Data Supporting the Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, but not (R)-Tianeptine, in the In Vivo Rat Novel Object Recognition (NOR) Test (GlobeNewswire)
Jul-17-23 07:00AM	Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder (GlobeNewswire)
Jul-10-23 07:00AM	Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 POWER Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity (GlobeNewswire) +7.50%
Jul-06-23 08:09AM	TNXP: Acquires Two Commercial Products for Migraine Treatment (Zacks Small Cap Research) -5.49%
07:00AM	Tonix Pharmaceuticals Comments on Two Long COVID Conferences Sponsored by the U.S. National Academies (GlobeNewswire)
Jul-03-23 07:00AM	Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products (GlobeNewswire)
Jun-28-23 03:21PM	Tonix Pharmaceuticals fibromyalgia study published in American College of Rheumatology (News Direct) +5.67%
Jun-26-23 07:00AM	Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC (GlobeNewswire) -10.63%
Jun-21-23 08:25AM	TNXP: Deep Dive into Tianeptine and its Novel Mechanism of Action for MDD (Zacks Small Cap Research)
Jun-15-23 07:00AM	Tonix Pharmaceuticals Announces Publication of Results from Phase 3 RELIEF Trial of TNX-102 SL for the Management of Fibromyalgia (GlobeNewswire) +5.49%
Jun-07-23 07:00AM	Tonix Pharmaceuticals Announces Data Presentations Involving TNX-1500 (anti-CD40L mAb) for the Prevention of Rejection in Kidney and Heart Allograft Transplantation in Animal Models at the 2023 American Transplant Congress (GlobeNewswire)
Jun-05-23 07:00AM	Tonix Pharmaceuticals Announces Presentation of Data Supporting Development of Racemic and Single (S)-Isomer Tianeptine, Plastogen Anti-Depressants, at the American Society of Clinical Psychopharmacology Meeting (GlobeNewswire) +5.32%
May-31-23 01:24PM	Tonix Pharmaceuticals shares breakthrough of TNX-601 ER study on patients with depression (News Direct) +9.82%
07:00AM	Tonix Pharmaceuticals Announces Presentations Involving TNX-1500 (anti-CD40L mAb) at the 2023 American Transplant Congress (GlobeNewswire)
May-30-23 07:00AM	Tonix Pharmaceuticals Announces Presentation at the 2023 BIO International Convention (GlobeNewswire)
May-25-23 04:05PM	Tonix Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
07:00AM	Tonix Pharmaceuticals Announces Poster Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting (GlobeNewswire)
May-24-23 07:00AM	Tonix Pharmaceuticals to Present at the June 1st Virtual Investor Summit (GlobeNewswire)
May-23-23 07:00AM	Tonix Pharmaceuticals Announces the Isolation and Characterization of the (S)-Isomer of Tianeptine, TNX-4300 (Estianeptine), Now Under Development for Psychiatric and Neurodegenerative Diseases (GlobeNewswire) -5.85%
May-22-23 07:00AM	Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin) (GlobeNewswire)
May-18-23 07:00AM	Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference (GlobeNewswire)
May-17-23 07:00AM	Tonix Pharmaceuticals Announces Pharmacology and Medicinal Chemistry Results that Reveal the Molecular Mechanism of Action of Tianeptine, the Active Ingredient of TNX-601 ER, in Treating Depression (GlobeNewswire)
May-09-23 01:00PM	Tonix Pharmaceuticals Announces 1-for-6.25 Reverse Stock Split (GlobeNewswire) -30.93%
May-08-23 07:00AM	Tonix Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights (GlobeNewswire)
May-04-23 07:00AM	Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant (GlobeNewswire) +5.08%
May-01-23 11:35AM	TNXP: Phase 2 Trial of TNX-601 ER Enrolling; New Treatment Concept in Depression (Zacks Small Cap Research) -7.69%
Apr-27-23 08:00AM	A New Depression Drug Being Developed by Tonix May Side-Step Treatment-Limiting Effects of Nearly All Current Antidepressants in the US (ACCESSWIRE)
Apr-24-23 11:34AM	Tonix Pharmaceuticals TNX-1500 monoclonal antibody published in American Journal of Transplantation (News Direct)
Apr-19-23 07:00AM	Tonix Pharmaceuticals Announces Presentations of Pre-Clinical Data on TNX-1700 in Syngeneic Models of Colorectal and Gastric Cancer at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Apr-17-23 07:00AM	Tonix Pharmaceuticals Announces Two Publications of Data in American Journal of Transplantation Showing TNX-1500 (anti-CD40L mAb) Prolongs Nonhuman Primate Renal and Heart Allograft Survival (GlobeNewswire)
Apr-13-23 02:12PM	Tonix Pharmaceuticals Fast Forwards Its Fibromyalgia, Migraine Studies (Benzinga)
07:00AM	Tonix Pharmaceuticals Expedites Fibromyalgia and Chronic Migraine Programs (GlobeNewswire)
Apr-06-23 04:15PM	Tonix Pharmaceuticals Presents Data from its Vaccine Development Program at the World Vaccine Congress (GlobeNewswire)
Apr-05-23 07:00AM	Tonix Pharmaceuticals Announces Poster Presentations at the American Association for Cancer Research Annual Meeting 2023 (GlobeNewswire)
Apr-04-23 07:00AM	Tonix Pharmaceuticals Announces Pipeline Prioritization Update for 2023 (GlobeNewswire)
Mar-30-23 07:00AM	Tonix Pharmaceuticals Presents Positive Efficacy and Safety Data from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the 5th International Congress on Controversies in Fibromyalgia (GlobeNewswire)
Mar-27-23 07:00AM	Tonix Pharmaceuticals Announces Oral Presentations at the World Vaccine Congress (GlobeNewswire)
Mar-23-23 04:15PM	Tonix Pharmaceuticals Presents Non-Clinical Data on TNX-2900 for the Potential Treatment of Hyperphagia in Adolescents and Young Adults with Prader-Willi Syndrome at the Rare Disease Innovation and Partnership Summit (GlobeNewswire) -8.29%
07:00AM	Tonix Pharmaceuticals Announces Oral Presentation and Poster at the 5th International Congress on Controversies in Fibromyalgia (GlobeNewswire)
Mar-22-23 07:00AM	Tonix Pharmaceuticals to Present at the 2023 Virtual March Investor Summit (GlobeNewswire) +5.89%
Mar-16-23 04:05PM	Tonix Pharmaceuticals Announces Presentation at the Rare Disease Innovation and Partnership Summit (GlobeNewswire) +6.64%
07:00AM	Tonix Pharmaceuticals Initiates Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Tianeptine Hemioxalate Extended-Release Tablets) for the Treatment of Major Depressive Disorder (MDD) (GlobeNewswire)
Mar-13-23 07:00AM	Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights (GlobeNewswire) +13.08%
Mar-07-23 07:00AM	Tonix Pharmaceuticals Announces Results from a Preclinical Study of Murine TNX-1700 Presented in a Poster at the Keystone Symposia, Cancer Immunotherapy: Mechanisms of Response Versus Resistance (GlobeNewswire) -10.35%
Feb-24-23 11:39AM	Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio (News Direct) -12.47%
Feb-23-23 04:15PM	Tonix Pharmaceuticals Announces New Board Member, R. Newcomb Stillwell (GlobeNewswire)
Feb-22-23 07:00AM	Tonix Pharmaceuticals Describes Emerging Research on the Incidence of Multi-Site Pain Symptoms in Long COVID Patients During Event Titled, Long COVID: What Will it Take to Accelerate Therapeutic Progress? (GlobeNewswire) -14.46%
Feb-16-23 07:00AM	Tonix Pharmaceuticals to Participate in Event Titled, Long COVID: What Will it Take to Accelerate Therapeutic Progress? (GlobeNewswire) -6.54%
Feb-13-23 09:30AM	New to The Street Announces its Line-up, Four Interviews on Episode #438, Airing on the Fox Business Network, Tonight, Monday, February 13, 2023, 10:30 PM PT (GlobeNewswire)
07:00AM	Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies (GlobeNewswire)
Feb-10-23 09:30AM	New to The Street / Newsmax TV Announces its Four Corporate Interviews on Episode #437, Broadcast, Saturday, February 11, 2023, 3:30 PM ET (GlobeNewswire) -5.41%
Feb-09-23 07:00AM	Tonix Pharmaceuticals Announces Publication of Paper in Viruses Highlighting the Companys Development of a Vaccine to Protect Against Monkeypox and Smallpox (TNX-801) (GlobeNewswire) -9.76%
Feb-06-23 07:00AM	Tonix Pharmaceuticals Initiates Enrollment in Phase 2 PREVENTION Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs (GlobeNewswire)
Feb-03-23 07:00AM	Tonix Pharmaceuticals to Participate in BIO CEO & Investor Conference (GlobeNewswire)
Feb-02-23 01:18PM	Tonix Pharmaceuticals Seeks To Bolster Its COVID-19 Pipeline With This New Acquisition (Benzinga)
12:15PM	Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies (News Direct)

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNXP

Tonix Pharmaceuticals Holding Corp

Upgrade your FINVIZ experience